Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023
Cancer Research and Treatment · 15.04.2026 · 58 (2) · 349-367
DOI: 10.4143/crt.2026.298 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.04.2026. Verfasst von Eun Hye Park und 10 weiteren Autor:innen. Beteiligte Einrichtung: Korea Central Cancer Registry, National Cancer Center, Goyang, Korea. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Health and Welfare, National Cancer Center.
Abstract (Originalsprache)
Purpose
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2023, with international comparisons.Materials and Methods Cancer incidence, survival, and prevalence rates were calculated using the Korea National Cancer Incidence Database (1999-2023), with survival follow-up until December 31, 2024. Mortality data were obtained from the Ministry of Data and Statistics, while international comparisons were based on GLOBOCAN data.
Results
In 2023, 288,613 newly diagnosed cancer cases (age-standardized rate [ASR], 288.6 per 100,000) and 85,271 deaths from cancer (ASR, 64.3 per 100,000) were reported. Among the incident cases, 145,452 (50.4%) were aged 65 years or older. Prostate cancer became the most common cancer among men for the first time. The proportion of localized-stage cancers increased from 45.6% in 2005 to 51.8% in 2023. Korea had the lowest cancer mortality among countries with similar incidence rates and the lowest mortality-to-incidence ratios for stomach, colorectal, and breast cancer. The 5-year relative survival rate (2019-2023) was 73.7% overall and 92.7% for localized-stage cancers. Over 2.73 million prevalent cases were identified in 2023, representing 5.3% of the Korean population.
Conclusion
These findings indicate that Korea’s cancer control efforts have contributed to early detection and improved survival outcomes. As Korea enters a super-aged society in 2025, cancer burden will continue to increase, requiring sustained and adaptive cancer control strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Korea Central Cancer Registry, National Cancer Center, Goyang, Korea.
- Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea.
- National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
- National Cancer Control Institute, National Cancer Center, Goyang, Korea.
Förderung
- Ministry of Health and Welfare
- National Cancer Center
Zitieren
APA
Park, E. H., Jung, K. W., Choi, S. H., Park, N. J., Kang, M. J., Yun, E. H., Kim, H. J., Kim, J. E., Choi, K. S., Yang, H. K., & Community of Population-Based Regional Cancer Registries (2026). Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023. Cancer Research and Treatment, 58(2), 349-367. https://doi.org/10.4143/crt.2026.298
Vancouver
Park EH, Jung KW, Choi SH, Park NJ, Kang MJ, Yun EH, et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023. Cancer Research and Treatment. 2026;58(2):349-367. doi:10.4143/crt.2026.298
BibTeX
@article{Park2026,
author = {Park, Eun Hye and Jung, Kyu-Won and Choi, Seo Hyun and Park, Nam Ju and Kang, Mee Joo and Yun, E Hwa and Kim, Hye-Jin and Kim, Jeong-Eun and Choi, Kui Son and Yang, Han-Kwang and Community of Population-Based Regional Cancer Registries, Community of Population-Based Regional Cancer Registries},
title = {Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023},
journal = {Cancer Research and Treatment},
year = {2026},
volume = {58},
number = {2},
pages = {349--367},
doi = {10.4143/crt.2026.298}
}
EUVIMED